---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287642780.md"
description: "Silexion Therapeutics shares are trading lower after the company announced a 1-for-10 reverse share split."
datetime: "2026-05-26T13:03:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287642780.md)
  - [en](https://longbridge.com/en/news/287642780.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287642780.md)
generator: "portal-rs"
---

# 

Silexion Therapeutics shares are trading lower after the company announced a 1-for-10 reverse share split.

### Related Stocks

- [SLXN.US](https://longbridge.com/en/quote/SLXN.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SLXNW.US](https://longbridge.com/en/quote/SLXNW.US.md)

## Related News & Research

- [Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancers](https://longbridge.com/en/news/295325850.md)
- [Silexion Therapeutics reports Q4 results](https://longbridge.com/en/news/279492728.md)
- [Silexion reports preclinical SIL204 data supporting Phase 2/3 development in KRAS-driven cancers](https://longbridge.com/en/news/294830800.md)
- [Silexion initiates Phase 2/3 SIL204 trial in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center](https://longbridge.com/en/news/294201019.md)
- [Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer | SLXN Stock News](https://longbridge.com/en/news/286425411.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**